Zhou Xing Qin, Chang Ya Zhou, Shen Chao Yan, Han Jie, Chang Ren An
Department of Radiotherapy, Affiliated Hospital of Nantong University, Nantong, China.
School of Medicine, Southeast University, Nanjing, China.
Front Pharmacol. 2022 Sep 30;13:1023314. doi: 10.3389/fphar.2022.1023314. eCollection 2022.
To evaluate the clinical efficacy and safety of Xiaoaiping injection combined with chemotherapy in the treatment of advanced gastric cancer by meta-analysis. Seven databases, including China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, Cochrane Library, PubMed, Embase, and Web of Science, were searched by computer for randomized controlled clinical trials of Xiaoaiping injection combined with chemotherapy in the treatment of gastric cancer. Risk of bias assessment and meta-analysis were performed by Review Manager 5.3 software. There were 16 articles that met the inclusion criteria, with a total of 1,236 patients, 617 in the observation group and 619 in the control group. The results of meta-analysis showed that the observation group was better than chemotherapy alone control group in RR [OR = 1.86, < 0.00001]; disease control rate (DCR) [OR = 2.45, < 0.00001]; Karnofsky performance status (KPS) score [OR = 3.21, < 0.00001] or [MD = 7.73, = 0.001]. In terms of biochemical indicators, Xiaoaiping significantly reduced inflammation factors level, including tumor necrosis factor alpha (TNF-α) [MD = -15.00, < 0.00001]; interleukin-6 (IL-6) [MD = -13.00, < 0.00001]; C-reaction protein (CRP) [MD = -5.80, < 0.00001]. Xiaoaiping could enhance immune function, significantly reducing myeloid-derived suppressor cells (MDSCs) [MD = -6.20, < 0.00001] and Treg [MD = -1.70, < 0.00001]. Xiaoaiping injection combined with chemotherapy could significantly decrease tumor markers, including carcinoembryonic antigen (CEA) [MD = -11.64, < 0.00001]; CA199 [MD = -33.57, = 0.02]; CA242 [MD = -20.66, < 0.00001]; CA125 [MD = -12.50, = 0.0005]. In the comparison of adverse reactions, the incidence rate of Xiaoaiping injection group was significantly lower than that of control group. The funnel plot showed that the left and right sides are basically symmetrical, and it can be considered that there is no obvious publication bias. Xiaoaiping injection combined with chemotherapy has better curative effect and less adverse reactions in the treatment of gastric cancer. However, limited by the quality of the included studies, more high-quality studies are still needed to be verified. : [https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022353842], identifier [CRD42022353842].
通过Meta分析评价消癌平注射液联合化疗治疗晚期胃癌的临床疗效及安全性。通过计算机检索中国知网（CNKI）、万方数据库、维普数据库、考克兰图书馆、PubMed、Embase及Web of Science这7个数据库，查找关于消癌平注射液联合化疗治疗胃癌的随机对照临床试验。采用Review Manager 5.3软件进行偏倚风险评估和Meta分析。共有16篇文章符合纳入标准，共1236例患者，观察组617例，对照组619例。Meta分析结果显示，观察组在相对危险度[比值比（OR）=1.86，P<0.00001]、疾病控制率（DCR）[OR=2.45，P<0.00001]、卡氏功能状态（KPS）评分[OR=3.21，P<0.00001]或[均差（MD）=7.73，P=0.001]方面均优于单纯化疗对照组。在生化指标方面，消癌平显著降低炎症因子水平，包括肿瘤坏死因子α（TNF-α）[MD=-15.00，P<0.00001]、白细胞介素-6（IL-6）[MD=-13.00，P<0.00001]、C反应蛋白（CRP）[MD=-5.80，P<0.00001]。消癌平可增强免疫功能，显著降低髓源性抑制细胞（MDSCs）[MD=-6.20，P<0.00001]和调节性T细胞（Treg）[MD=-1.70，P<0.00001]。消癌平注射液联合化疗可显著降低肿瘤标志物，包括癌胚抗原（CEA）[MD=-11.64，P<0.00001]、CA199[MD=-33.57，P=0.02]、CA242[MD=-20.66，P<0.00001]、CA125[MD=-12.50，P=0.0005]。在不良反应比较中，消癌平注射液组的发生率显著低于对照组。漏斗图显示左右两侧基本对称，可认为无明显发表偏倚。消癌平注射液联合化疗治疗胃癌疗效较好且不良反应较少。然而，受纳入研究质量的限制，仍需要更多高质量研究进行验证。：[https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022353842]，标识符[CRD42022353842]
